Stock Analysis
Amgen IncAMGN
P/E 26.74×· 5Y range 14.56–48.06×· 70th percentile of history
Sector: Healthcare · Industry: Biotechnology
AnalystsHold43 analystsP/E 26.7× sits at the 70th percentile of its 5.0978781656399725-year history.
Cash covers 24% of debt · Q2 2026.
PMP Verdict
High quality, fairly valued
Strengths
- Profitability95
- Quality84
Risks
- Financial Health37
Strong fundamentals at a reasonable valuation.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓ROE 74.8% — efficient capital deployment
What's happening with AMGN
Profile
Strong profitability, moat and earnings quality; financial health and valuation lag behind.
How is each axis scored?
- Valuation41/100 · Weak
- P/E vs own history (70th pct)5/25
- FCF yield (4.4%)12/25
- P/S (6.1x)12/25
- EV/EBIT (24.1x)12/25
- Growth61/100 · Moderate
- Revenue CAGR (9.1%)12/25
- Net income CAGR (7.0%)12/25
- EPS CAGR 5Y (8.5%)12/25
- Fwd implied growth (55.9%)25/25
- Profitability95/100 · Strong
- ROIC (16.4%)20/25
- ROE (74.8%)25/25
- Net margin (23.0%)25/25
- Operating margin (30.0%)25/25
- Financial Health37/100 · Weak
- Altman Z (1.87)10/25
- Current ratio (1.37)12/25
- Interest coverage (4.6x)10/25
- Net cash / debt (D/A 45%)5/25
- Quality84/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-2.63)25/25
- FCF conversion (116%)25/25
- Margin stability (σ 9.9%)12/25
- Moat88/100 · Strong
- ROIC >12% years (8/10 yrs)20/25
- Median gross margin (75.7%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 8.7%)18/25
About Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Show more
Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Headquarters: THOUSAND OAKS, CA · Employees: 31,500 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
41D+P/E (TTM)26.6xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 14.6x–48.1x · 70th pct
P/FCF21.6xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield4.4%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 3.5%–8.2% · 16th pct
P/S (TTM)6.10xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 4.2x–6.5x · 98th pct
EV/EBIT24.1xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 15.0x–36.3x · 61st pct
EV/Sales7.2xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E17.1xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio19.89xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio5.08D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield2.26%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio66.7%C
Grade C: HighDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
95A+ROIC16.4%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE74.8%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA9.5%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin23.0%A
Grade A: HighNet Income / Revenue
Operating Margin30.0%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin69.5%A
Grade A: PremiumGross Profit / Revenue
FCF Margin26.7%A
Grade A: HighFCF / Revenue
True FCF Margin25.4%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
61BRevenue CAGR9.1%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR7.0%C
Grade C: OkCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)8.5%C
Grade C: OkCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth55.9%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-6.5%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income5.6%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.3%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
37DAltman Z-Score1.87C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.37xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.13xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage4.6xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment4.3yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT3.8xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity4.90xD
Grade D: HighDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.24xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
84APiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.63A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion116.4%A
Grade A: StrongFCF / Net Income
Margin Stability9.9%C
Grade C: AverageEBIT margin std deviation. Lower = stable
Capex / Revenue6.0%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.41xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Khosla Rachna Filed | Khosla Rachna | Option exercise | -1252 | |
Khosla Rachna Filed | Khosla Rachna | SellOpen market sale | -1252 | |
Khosla Rachna Filed | Khosla Rachna | Option exercise | +1.3K | |
Khosla Rachna Filed | Khosla Rachna | SellOpen market sale | -2000 | |
Busch Matthew C. Filed | Busch Matthew C. | Grant / award | +730 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Drake Michael V Filed | Drake Michael V | Grant / award | +64 | |
ISHRAK OMAR Filed | ISHRAK OMAR | Grant / award | +85 | |
HOLLEY CHARLES M Filed | HOLLEY CHARLES M | Grant / award | +103 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
88AROIC >12% Years8/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)75.7%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor8.7%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$16.17
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$25.86
Cash & short-term investments per share (Finnhub)
Book Value / Share$21.60
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$57.30B
Total debt obligations (short + long term)
Cash & Equiv.$13.99B
Cash and short-term investments
Net Debt$43.31B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$11.69B
Shareholders' equity (book value)
Asset / Liability1.14xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$232.48B
Current Market Capitalization
Beta0.44B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Amgen Inc (AMGN)
Amgen Inc meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 1.87 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -2.63 suggests a low likelihood of earnings manipulation. Amgen Inc converts about 27% of revenue into free cash flow — strong cash generation.
- Takes ~4.3 years to repay net debt from free cash flow.
- Return on equity of 74.8% is well above the market average.
- The stock currently yields 2.3% in dividends.
See how AMGN ranks on the Capex Tracker — top 50 capital spenders compared.
No significant market moves for AMGN in the last 30 days.
See AMGN move history →Frequently Asked Questions about AMGN
What is the current Amgen Inc (AMGN) stock price?
AMGN is trading at $432.49 at the last market close, down 0.35% on the session. PreMarketPrice tracks AMGN pre-market, intraday and after-hours prices.
Is AMGN stock a buy right now?
PreMarketPrice's quantitative model rates Amgen Inc's financial health at 37/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is AMGN stock overvalued?
Amgen Inc trades at a trailing P/E of 26.6 and our valuation score rates it 41/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Amgen Inc report earnings?
No confirmed earnings date is currently scheduled for AMGN. The Earnings section lists recent reports and updates as dates are announced.
What sector does Amgen Inc operate in?
Amgen Inc operates in the Healthcare sector, within the Biotechnology industry. The Related Stocks section lists sector peers for comparison.
What does Amgen Inc do?
Amgen is a leader in biotechnology-based human therapeutics.
About Amgen Inc (AMGN) Stock
Amgen Inc (AMGN) is a US-listed stock operating in the Healthcare sector, specifically the Biotechnology industry. As of the latest update, Amgen Inc is trading at $432.49, down 0.35% on the day with a market capitalization of $232.5 billion. The financial health score for AMGN is 37/100, which indicates weak financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for AMGN stock.
AMGN Stock Analysis & Key Metrics
On PreMarketPrice, you can track Amgen Inc (AMGN) across multiple dimensions:
- Pre-market price & movement: Real-time AMGN stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for AMGN with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Amgen Inc across multiple reporting periods.
- Financial health score: A composite score of 37/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for AMGN.
- Sector peers: Compare AMGN against 6 other healthcare stocks on key financial metrics.
Is AMGN a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Amgen Inc (AMGN) as an investment. The financial health score of 37/100 suggests weak financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Amgen Inc (AMGN) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.